Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.

ABSTRACT: Amiselimod (MT-1303) is a novel and selective sphingosine 1-phosphate receptor-1 (S1P₁) modulator with a more favorable cardiac safety profile than other S1P₁ receptor modulators. In this study, we evaluated the effects of MT-1303 on the progression of lupus nephritis in two well-known murine systemic lupus erythematosus (SLE) models, MRL/lpr and NZBWF1 mice, compared with those of FK506. Daily oral doses of 0.1 and 0.3 mg/kg MT-1303 not only inhibited the development of lupus nephritis when administered before onset in MRL/lpr and NZBWF1 mice but also improved symptoms of lupus nephritis when administered after onset in MRL/lpr mice. Its efficacy in these models was more potent or comparable to that of FK506 (1 and 3 mg/kg). In histological analy

SUBMITTER: Sugahara K 

PROVIDER: S-EPMC6942851 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature